Public beta© 2026 Adaptrex, LLC
Public beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Sbir Phase I: a Novel Low Cost Intradermal Delivery Platform for Nucleic Acid Vaccines -the Broader Impact/commercial Potential of This Small Business Innovation Research (SBIR) Phase I Project Is a New Portable Low Cost Vaccine Delivery Platform for Nucleic Acid Vaccines, Commonly Used to Treat Infectious Diseases and Cancer. Current Vaccines Are Delivered Using Lipid Nanoparticles (LNPS) Which Are Generally Considered Complex and Generally More Costly to Produce. Furthermore They Can Exhibit Undesirable Side Effects. These Challenges Have Caused a Steady Decline in Actual Adoption Despite Their Demonstrated Efficacy. This Project Aims to Develop a New Technology to Deliver Nucleic Acid Vaccines Without LNPS or Carriers in General, Using a Simpler Scalable Approach Leveraging Electroporation. If Successful, This Platform Could Expand Access to Vaccine Delivery With Fewer Side Effects, Improve Their Tolerability/acceptability, and Support Ultra-rapid Deployment for Biosecurity Threats, to Provide a New Delivery Method for Vaccinations. This Small Business Innovation Research (SBIR) Phase I Project Will Demonstrate the Feasibility of Delivering Naked Nucleic Acid Vaccines Without Lipid Nanoparticles (LNPS) Using a Simple Handheld Pen Design. the Device Delivers Electrical Pulses Through Microelectrodes to Create Temporary Pores in Skin Cells Allowing Direct Vaccine Delivery to Immune Cells Without Systemic Exposure. in This Project, the Pen Will Be: 1) Optimized in Vivo to Maximize Gene Delivery and Protein Expression by Varying Electric Pulse Voltage, Duration, and Mechanical Micro Needle Configurations and 2) Benchmarked for Their Vaccine Delivery Effectiveness Against an Fda-approved Vaccine With the Goal of Showing Superior or Comparable Immune Responses Despite Eliminating Lipid Nanoparticles, in a Mouse Model. These Result Will Demonstrate Preclinical Feasibility of a Novel Delivery Platform to Match LNP Efficacy for Vaccines While Reducing Cost, Complexity, and Side Effects Compared to Existing Systems. This Award Reflects NSF'S Statutory Mission and Has Been Deemed Worthy of Support Through Evaluation Using the Foundation's Intellectual Merit and Broader Impacts Review Criteria.- Subawards Are Not Planned for This Award.
Committed
$304,742
Paid out
$279.7K
92%
Committed, not yet paid
$25.0K
8%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.